- Home
- CCCC vs VLOS Comparison
CCCC vs VLOS Comparison
Compare CCCC & VLOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCCC | VLOS |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 388.1M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CCCC | VLOS |
|---|---|---|
| Price | $3.73 | $10.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 141.1K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.69 | $10.65 |
| 52 Week High | $5.17 | $10.90 |
Technical Indicators
Market Signals| Indicator | CCCC | VLOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 58.95 |
| Support Level | $3.42 | $10.65 |
| Resistance Level | $3.91 | $10.90 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 47.46 | 46.00 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
About VLOS Velos Acquisition I Corp. Class A Ordinary shares
Velos Acquisition I Corp, formerly M3-Brigade Acquisition V Corp, is a blank check company.